SLNO

Soleno Therapeutics Inc

SLNO, USA

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

https://soleno.life

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SLNO
stock
SLNO

Soleno Therapeutics Gains Momentum Following Wolfe Research Favorable Rating timothysykes.com

Read more →
SLNO
stock
SLNO

Soleno Therapeutics, Inc. $SLNO Shares Sold by Holocene Advisors LP MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$113.5385

Analyst Picks

Strong Buy

5

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

5.77

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

5.26 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

4.34 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

66.09 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.21

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 102.33% of the total shares of Soleno Therapeutics Inc

1.

HHG PLC

(9.9878%)

since

2025/06/30

2.

Vivo Capital, LLC

(7.4481%)

since

2025/06/30

3.

Adage Capital Partners Gp LLC

(6.7287%)

since

2025/06/30

4.

T. Rowe Price Associates, Inc.

(6.5133%)

since

2025/06/30

5.

FMR Inc

(6.2807%)

since

2025/06/30

6.

BlackRock Inc

(5.3528%)

since

2025/06/30

7.

Vanguard Group Inc

(4.6812%)

since

2025/06/30

8.

venBio Select Advisor LLC

(3.8574%)

since

2025/06/30

9.

Citadel Advisors Llc

(2.8322%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(2.8128%)

since

2025/07/31

11.

Westfield Capital Management Company, L.P.

(2.6903%)

since

2025/06/30

12.

State Street Corp

(2.6437%)

since

2025/06/30

13.

T. Rowe Price All-Cap Opportunities Fund

(2.3821%)

since

2025/07/31

14.

Holocene Advisors, LP

(2.1696%)

since

2025/06/30

15.

T. Rowe Price US All-Cap Opp Eq Comp

(2.1133%)

since

2025/06/30

16.

Nantahala Capital Management, LLC

(1.8842%)

since

2025/06/30

17.

iShares Russell 2000 ETF

(1.8212%)

since

2025/08/31

18.

Polar Capital Biotech S Inc

(1.7405%)

since

2025/07/31

19.

T. Rowe Price Health Sciences

(1.7399%)

since

2025/07/31

20.

Janus Henderson Global Life Sciences

(1.7045%)

since

2025/06/30

21.

Janus Henderson Global Life Sciences D

(1.7045%)

since

2025/06/30

22.

Geode Capital Management, LLC

(1.698%)

since

2025/06/30

23.

The Carlyle Group Inc

(1.6201%)

since

2025/06/30

24.

Strategic Advisers Fidelity US TtlStk

(1.5993%)

since

2025/07/31

25.

Polar Capital Holdings PLC

(1.5382%)

since

2025/06/30

26.

Fidelity Select Health Care

(1.4677%)

since

2025/07/31

27.

Janus Henderson Glb Life Scn I2 USD

(1.4096%)

since

2025/07/31

28.

Janus Global Life Science AUSD

(1.4096%)

since

2025/06/30

29.

Emerald Advisers, LLC

(1.2662%)

since

2025/06/30

30.

Pictet Asset Manangement SA

(1.2269%)

since

2025/06/30

31.

Amvescap Plc.

(1.2155%)

since

2025/06/30

32.

Millennium Management LLC

(1.1924%)

since

2025/06/30

33.

American Funds SMALLCAP World A

(1.1569%)

since

2025/06/30

34.

SPDR® S&P Biotech ETF

(1.0887%)

since

2025/08/31

35.

US Small-Cap Growth II Equity Comp

(1.0161%)

since

2025/06/30

36.

T. Rowe Price New Horizons

(0.9852%)

since

2025/07/31

37.

Janus Henderson Triton D

(0.8376%)

since

2025/06/30

38.

Janus Henderson US SMID Cap Growth

(0.8376%)

since

2025/06/30

39.

Janus Henderson US SMID Cap Growth MA

(0.8376%)

since

2025/06/30

40.

Fidelity Contrafund

(0.8372%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.215

Latest Release

Date

2025-09-30

EPS Actual

0.47

EPS Estimate

0.05

EPS Difference

0.42

Surprise Percent

840%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(7.5)
GARP
Fair GARP(6)
Growth
Moderate Growth(4.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8.5)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.